Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Assets (2022 - 2025)

Historic Assets for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $448.3 million.

  • Centessa Pharmaceuticals' Assets fell 2647.38% to $448.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $448.3 million, marking a year-over-year decrease of 2647.38%. This contributed to the annual value of $576.8 million for FY2024, which is 6011.23% up from last year.
  • Centessa Pharmaceuticals' Assets amounted to $448.3 million in Q3 2025, which was down 2647.38% from $492.1 million recorded in Q2 2025.
  • Centessa Pharmaceuticals' Assets' 5-year high stood at $609.7 million during Q3 2024, with a 5-year trough of $328.2 million in Q1 2024.
  • Moreover, its 4-year median value for Assets was $448.3 million (2025), whereas its average is $462.9 million.
  • Its Assets has fluctuated over the past 5 years, first crashed by 3063.07% in 2023, then skyrocketed by 6157.21% in 2024.
  • Quarter analysis of 4 years shows Centessa Pharmaceuticals' Assets stood at $444.3 million in 2022, then fell by 18.92% to $360.2 million in 2023, then soared by 60.11% to $576.8 million in 2024, then dropped by 22.28% to $448.3 million in 2025.
  • Its Assets was $448.3 million in Q3 2025, compared to $492.1 million in Q2 2025 and $527.8 million in Q1 2025.